Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia

Overview

The aim of this study is to determine whether high high density lipoprotein-cholesterol(HDL-C) level and low Cholesteryl Ester Transfer Protein(CETP) activity is atherogenic or not in subjects who received health checkups. We investigate the association between CETP activities and the severity of atherosclerosis assessed by intima-media thickness (IMT) and compare the atherogenic change between in subjects with high HDL-C level, low HDL-C level, high CETP activities and low CETP activities by examining the morbidity rate of atherogenic diseases, the rate of ischemic electrocardiography(ECG) change, Calc Score of artery from chest X-ray, Ankle Brachial Index/Pulse Wave Velocity and various serum atherogenic markers. And we also examine the correlation between normal lipid profile and concentration, activity and function of surface lipoprotein in subjects with variety of lipoprotein levels, including patients with hyper-LDL-cholesterolemia, hyper-HDL-cholesterolemia with low or no CETP activity, patients with high level of remnant cholesterol or hyperlipoproteinemia of apolipoprotein(Apo)B-48.

Full Title of Study: “Investigation of Relationship Between Cholesteryl Ester Transfer Protein Deficiency and Carotid/Coronary Atherosclerosis in Patients With Hyperalphalipoproteinemia”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: March 2016

Clinical Trial Outcome Measures

Primary Measures

  • Difference of Ischemic changes of ECG among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Ischemic changes of ECG was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Calc Score of Aorta by Chest X-ray among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Calc Score of Aorta by Chest X-ray was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Ankle Brachial Index (ABI) among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Ankle Brachial Index (ABI) was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Pulse Wave Velocity (baPW) among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Pulse Wave Velocity (baPW) was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of IMT and Plaque Score of Carotid artery among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of IMT and Plaque Score of Carotid artery was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of CETP activity between normolipidemic subjects and patients with dyslipidemia (including high HDL-C level)
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of CETP activity was assessed between in those who do not satisfy any of these three conditions (normolipidemic subjects) and those who satisfy any of these three conditions (patients with dyslipidemia); LDL-C:100 mg/dl and above, HDL:80 mg/dl and above, TG:150 mg/dl and above.
  • Difference of Antioxidant activity between normolipidemic subjects and patients with dyslipidemia (including high HDL-C level)
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Antioxidant activity was assessed between normolipidemic subjects and patients with dyslipidemia;HDL from subjects’ serum samples will be added to LDL with 2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH).
  • Difference of Monocyte chemoattractant protein-1 (MCP-1) concentration between normolipidemic subjects and patients with dyslipidemia (including high HDL-C level)
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of MCP-1 concentration was assessed between normolipidemic subjects and patients with dyslipidemia
  • Difference of Cholesterol efflux between normolipidemic subjects and patients with dyslipidemia (including high HDL-C level)
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Cholesterol efflux by HDL from macrophage was assessed between normolipidemic subjects and patients with dyslipidemia
  • Difference of Proteome analysis of lipoproteins between normolipidemic subjects and patients with dyslipidemia (including high HDL-C level)
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Proteome analysis of lipoproteins (HDL, LDL, remnant binding protein) was assessed between normolipidemic subjects and patients with dyslipidemia

Secondary Measures

  • Difference of Fasting blood glucose and HbA1c among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Fasting blood glucose and HbA1c was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of waist circumference among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of waist circumference was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Smoking habits, alcohol taking habits and fitness habits among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Smoking habits, alcohol taking habits and fitness habits was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of BMI among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of BMI was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Blood Pressure among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Blood Pressure was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of 75g glucose tolerance test and calculated homeostasis model assessment of insulin resistance (HOMA-IR) among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of 75g glucose tolerance test and calculated homeostasis model assessment of insulin resistance (HOMA-IR) was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Total Cholesterol(TC) among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Total Cholesterol(TC) was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of low density lipoprotein-cholesterol (LDL-C) among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of low density lipoprotein-cholesterol (LDL-C) was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of triglyceride (TG) among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of triglyceride (TG) was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Serum adiponectin among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference ofSerum adiponectin was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Apolipoprotein (apo)B-48 concentrations among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Apolipoprotein (apo)B-48 concentrations was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Remnant lipoprotein (RemL-C) among subjects with low/high CETP mass/activity and HDL-C level
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Remnant lipoprotein (RemL-C) was assessed between in subjects with high CETP mass/activity and in those with low CETP mass/activity, and between in subjects with high HDL-C level and in those with low HDL-C level
  • Difference of Lipoprotein Profile between normolipidemic subjects and patients with dyslipidemia (including high HDL-C level)
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of Lipoprotein Profile analyzed by high performance liquid chromatography(HPLC) method was assessed between in those who do not satisfy any of these three conditions (normolipidemic subjects) and those who satisfy any of these three conditions (patients with dyslipidemia); LDL-C:100 mg/dl and above, HDL:80 mg/dl and above, TG:150 mg/dl and above.
  • Difference of apolipoprotein(apo)B-48 concentrations between normolipidemic subjects and patients with dyslipidemia (including high HDL-C level)
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of apoB-48 concentrations was assessed between in normolipidemic subjects and in patients with dyslipidemia
  • Difference of Remnant lipoprotein (RemL-C) between normolipidemic subjects and patients with dyslipidemia (including high HDL-C level)
    • Time Frame: participants will be followed for the duration of hospital stay(2 days)
    • The difference of RemL-C was assessed between in normolipidemic subjects and in patients with dyslipidemia

Participating in This Clinical Trial

Inclusion Criteria

Subjects who are at the age of 40 and above and undergo annual health check in Omagari area including Daisen city and Yokote city and who provide written informed consent. Exclusion criteria:

1. Those who do not provide written informed consent. 2. Those who are not able to take tests. 3. Those who are regarded not adequate as subject of this study by their physicians.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Osaka University
  • Collaborator
    • Merck Sharp & Dohme LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shizuya Yamashita, MD, PhD, FAHA, FJCC, Study Chair, Osaka University Graduate School of Medicine
    • Etsuko Fushimi, MD, PhD, Study Director, Hiraga General Hospital
    • Hiroshi Itoh, MD, PhD, Study Director, Akita University Graduate School of Medicine
    • Norimichi Nakajima, MD, Study Director, Nakajima Naika Clinic
    • Yoshinobu Ikeda, MD, Study Director, Ikeda Clinic
    • Yuji Matsuzawa, MD, PhD, Study Director, Sumitomo Hospital
  • Overall Contact(s)
    • Shizuya Yamashita, MD, PhD, FAHA, FJCC, +81-6-6879-3633, shizu@cardiology.med.osaka-u.ac.jp

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.